phase 3 retatrutide Lilly's triple agonist delivers up to 71.2 lbs of weight loss New Retatrutide Phase 3 Trial

The most well-known GLP-1 receptor agonists include semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon)

Genetic limitations of these genes lead to less efficient enzymes, thus lower glutathione levels and a greater susceptibility to oxidative stress and related disease and divergence of development

In preclinical models and early clinical trials, glucagon receptor activation increased total energy expenditure, meaning the body burns more calories even at rest

Standardized follow-up schedules contribute valuable safety and efficacy data